Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis | Zendy

Ralf Gold | Zendy; Ludwig Kappos | Zendy; Douglas L. Arnold | Zendy; Amit BarOr | Zendy; Gavin Giovani | Zendy; Krzysztof Selmaj | Zendy; Carlo Tornatore | Zendy; Marianne T. Sweetser | Zendy; Minhua Yang | Zendy; Sarah Sheikh | Zendy; Katherine Dawson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

Author(s) -

Ralf Gold,

Ludwig Kappos,

Douglas L. Arnold,

Amit BarOr,

Gavin Giovani,

Krzysztof Selmaj,

Carlo Tornatore,

Marianne T. Sweetser,

Minhua Yang,

Sarah Sheikh,

Katherine Dawson

Publication year - 2012

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1114287

Subject(s) - placebo , medicine , multiple sclerosis , clinical endpoint , regimen , placebo controlled study , gastroenterology , randomized controlled trial , double blind , immunology , pathology , alternative medicine

BG-12 (dimethyl fumarate) was shown to have antiinflammatory and cytoprotective properties in preclinical experiments and to result in significant reductions in disease activity on magnetic resonance imaging (MRI) in a phase 2, placebo-controlled study involving patients with relapsing-remitting multiple sclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research